Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.

F. Vincenti,¹ J. Medina Pestana,² M. Abouljoud,³ B. Bresnahan,⁴ V. Duro Garcia,⁵ L. Mulloy,⁶ K. Rice,⁷ L. Rostaing,⁸ C. Zayas,⁹ K. Calderon,¹⁰ U. Meier-Kriesche,¹⁰ M. Polinsky,¹⁰ H. Zhao,¹⁰ C. Larsen.¹¹

¹UCSF, San Francisco
²Hosp do Rim, Sao Paulo, Brazil
³Henry Ford Hosp, Detroit
⁴Med Coll of Wisconsin, Milwaukee
⁵Hospital Dom Vicente Scherer, Porto Alegre, Brazil
⁶Georgia Regents Univ, Augusta
⁷Baylor Univ Med Ctr, Dallas
⁸Univ Hosp and INSERM U563, IFR-BMT, Toulouse, France
⁹Piedmont Hosp, Atlanta
¹⁰BMS, Lawrenceville
¹¹Emory Univ Transplant Center, Atlanta.

Meeting: 2016 American Transplant Congress

Abstract number: D139

Keywords: African-American, Kidney transplantation, Renal function

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Novel Agents

Session Type: Poster Session

Date: Tuesday, June 14, 2016

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT, bela was associated with superior graft survival and renal function vs CsA. We examined outcomes by race in BENEFIT.

Recipients of living or SCD kidneys were randomized to bela more intense (MI), bela less intense (LI), or CsA. All randomized, transplanted pts were analyzed to 7 yrs. Time to death or graft loss was compared between regimens with Cox regression. Race and treatment effect were assessed. The interaction of treatment and race was also considered. GFR was estimated from months 1–84 using a repeated measures model.

Of 666 randomized pts, 55 were black. SAE rates in black vs non-black pts were similar. In both subgroups, estimated mean GFR increased over 7 yrs for bela but declined for CsA. In black pts, GFR slopes diverged over time between bela LI and CsA (P<.0001), but not bela MI and CsA (P=.11). In non-black pts, the interaction of the treatment vs time effect deriving from the model favored each bela regimen vs CsA (P<.0001).

In this post-hoc analysis, outcomes were similar in bela-treated black and non-black pts. While estimated mean GFR was higher in black pts treated with bela vs CsA, the number of black pts was small.

	Black (n=55)			Non-black (n=611)
	Bela MI	Bela LI	CsA	Bela MI	Bela LI	CsA
Pts evaluable for death/graft loss at month 84, n/N	9/15	17/23	11/17	144/204	146/203	120/204
SAE, %	73	65	88	71	69	75
Estimated mean GFR at month 84, mL/min/1.73 m²	65.1	82.3	41.5	70.6	71.0	45.2

CITATION INFORMATION: Vincenti F, Medina Pestana J, Abouljoud M, Bresnahan B, Duro Garcia V, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Zhao H, Larsen C. Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT. Am J Transplant. 2016;16 (suppl 3).

To cite this abstract in AMA style:

Vincenti F, Pestana JMedina, Abouljoud M, Bresnahan B, Garcia VDuro, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Zhao H, Larsen C. Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-in-black-vs-non-black-patients-administered-belatacept-bela-or-cyclosporine-csa-in-benefit/. Accessed May 9, 2025.

« Back to 2016 American Transplant Congress